The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration After Intravenous Injection of Flurbiprofen Axetil in Human Subjects
Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flu...
Saved in:
Published in | Frontiers in pharmacology Vol. 12; p. 646196 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
30.04.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1663-9812 1663-9812 |
DOI | 10.3389/fphar.2021.646196 |
Cover
Abstract | Background:
Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil.
Methods:
A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry.
Results:
R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points (
p
< 0.05) except at 30 or 40 min, and lower in CSF at all time points (
p
< 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC
0–50
for R (−)-flurbiprofen was larger in plasma and smaller in CSF (
p
< 0.05 for both), and accordingly smaller CSF/plasma AUC
0–50
ratio (
p
< 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725,
p
< 0.001) as well as in CSF (r = 0.718,
p
< 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250,
p
= 0.037), but not R (−)-flurbiprofen.
Conclusion:
Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen. |
---|---|
AbstractList | Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (-)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil.
A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5-50 min) after subarachnoid puncture and before actual spinal anesthesia. R (-)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography-tandem mass spectrometry.
R (-)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46-34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (-)-flurbiprofen concentration was significantly higher in plasma at all time points (
< 0.05) except at 30 or 40 min, and lower in CSF at all time points (
< 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (-)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC
for R (-)-flurbiprofen was larger in plasma and smaller in CSF (
< 0.05 for both), and accordingly smaller CSF/plasma AUC
ratio (
< 0.05). There was a positive correlation between R (-)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725,
< 0.001) as well as in CSF (r = 0.718,
< 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = -0.250,
= 0.037), but not R (-)-flurbiprofen.
Distribution of R (-)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (-)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen. Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry. Results: R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points ( p < 0.05) except at 30 or 40 min, and lower in CSF at all time points ( p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC 0–50 for R (−)-flurbiprofen was larger in plasma and smaller in CSF ( p < 0.05 for both), and accordingly smaller CSF/plasma AUC 0–50 ratio ( p < 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250, p = 0.037), but not R (−)-flurbiprofen. Conclusion: Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen. Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (-)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5-50 min) after subarachnoid puncture and before actual spinal anesthesia. R (-)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography-tandem mass spectrometry. Results: R (-)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46-34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (-)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (-)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0-50 for R (-)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0-50 ratio (p < 0.05). There was a positive correlation between R (-)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = -0.250, p = 0.037), but not R (-)-flurbiprofen. Conclusion: Distribution of R (-)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (-)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (-)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil. Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5-50 min) after subarachnoid puncture and before actual spinal anesthesia. R (-)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography-tandem mass spectrometry. Results: R (-)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46-34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (-)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (-)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0-50 for R (-)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0-50 ratio (p < 0.05). There was a positive correlation between R (-)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = -0.250, p = 0.037), but not R (-)-flurbiprofen. Conclusion: Distribution of R (-)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (-)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen. Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil.Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry.Results: R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0–50 for R (−)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0–50 ratio (p < 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250, p = 0.037), but not R (−)-flurbiprofen.Conclusion: Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen. |
Author | Yao, Han Feng, Yi Zhang, Hong Luo, Xingxian An, Haiyan Feng, Wanyu |
AuthorAffiliation | 1 Department of Anesthesiology, Peking University People’s Hospital, Beijing , China 2 Department of Pharmacy, Peking University People’s Hospital, Beijing , China |
AuthorAffiliation_xml | – name: 2 Department of Pharmacy, Peking University People’s Hospital, Beijing , China – name: 1 Department of Anesthesiology, Peking University People’s Hospital, Beijing , China |
Author_xml | – sequence: 1 givenname: Han surname: Yao fullname: Yao, Han – sequence: 2 givenname: Xingxian surname: Luo fullname: Luo, Xingxian – sequence: 3 givenname: Hong surname: Zhang fullname: Zhang, Hong – sequence: 4 givenname: Haiyan surname: An fullname: An, Haiyan – sequence: 5 givenname: Wanyu surname: Feng fullname: Feng, Wanyu – sequence: 6 givenname: Yi surname: Feng fullname: Feng, Yi |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33995057$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1u1DAQxyNUREvpA3BBPm6FsvgjcZIL0mpF6UqVQLScLcced71K7OAkVXkDzrwBr8aT4E1a1EXCB3s8H7-_NDMvkyPnHSTJa4KXjJXVO9NtZVhSTMmSZ5xU_FlyQjhnaVUSevTEPk7O-n6H42FVxXj2Ijlm0cpxXpwkv262gNa-7WSwvXfIG_S5kX0rkXQarSFAHXzfWScbdNGMVqMvi98_fp6nU_x68fY8je5Q2y54Ay6inAI3BDnYSFuZAQLa7P934PzYR3sHaopFpYPK1T0MtkHWocuxlQ5dj_U-tX-VPDey6eHs4T1Nvl58uFlfplefPm7Wq6tUZTwfUqBYqlqVUtd5TTijBjQvaB5vUFhLTTIw2ijAhaxyXhaygCzXWa1JTmOQnSabmau93Iku2FaG78JLKyaHD7dChsGqBkRR1pyaCK1Ine2FGY16siqM5EQqElnvZ1Y31i3ouSPNAfQw4uxW3Po7EceFGeYRsHgABP9thH4Qre0VNI10ENsoaE7LjBE8pb55qvVX5HHGMaGYE1ScZB_ACGWHaT5R2jaCYLFfKDEtlNgvlJgXKlaSfyof4f-v-QOprtOP |
CitedBy_id | crossref_primary_10_1021_acsnano_4c01245 crossref_primary_10_1002_chir_23531 crossref_primary_10_2147_JPR_S399454 crossref_primary_10_1016_j_jddst_2024_105407 |
Cites_doi | 10.1046/j.1471-4159.2000.0742094.x 10.1016/0006-2952(88)90762-9 10.2174/138920009789895480 10.11669/cpj.2013.13.014 10.1111/j.1365-2125.2010.03720.x 10.1097/00000542-200603000-00005 10.1016/j.apmr.2011.05.009 10.1002/jps.2600770805 10.1016/0014-2999(94)90247-x 10.1016/0006-2952(91)90039-8 10.1136/rapm-2019-100700 10.1007/bf00266343 10.1038/sj.clpt.6100304 10.1371/journal.pone.0010628 10.1002/ddr.21314 10.1111/j.1365-2125.1994.tb04295.x 10.3390/molecules180910747 10.1007/s00228-003-0574-6 10.1096/fj.00-0130fje10.1096/fasebj.15.1.2 10.1002/brb3.1290 10.1111/j.1365-2125.1992.tb04054.x 10.1055/s-0031-1300446 10.5414/CP203092 10.1016/j.pharmthera.2005.02.004 10.1186/1471-2474-10-127 10.1016/0169-409X(95)00123-O 10.1016/j.pbb.2008.06.008 10.1038/35068566 10.1016/j.asjsur.2017.01.002 10.2165/00003088-200645070-00008 10.1111/j.1365-2125.2007.02846.x 10.2147/JPR.S176475 10.1016/0024-3205(94)00555-9 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng. Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng. 2021 Yao, Luo, Zhang, An, Feng and Feng |
Copyright_xml | – notice: Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng. – notice: Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng. 2021 Yao, Luo, Zhang, An, Feng and Feng |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fphar.2021.646196 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Yao et al |
EISSN | 1663-9812 |
ExternalDocumentID | oai_doaj_org_article_78b62f0da91b4e20a3232fa97fa61ac1 PMC8120306 33995057 10_3389_fphar_2021_646196 |
Genre | Journal Article |
GrantInformation_xml | – fundername: National Key Research and Development Program of China grantid: 2018YFC2001905 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c465t-e20acbc8adb5b1632fed6725ed6ec0dad14efdfce07a95687a7e45d4bd152d143 |
IEDL.DBID | M48 |
ISSN | 1663-9812 |
IngestDate | Wed Aug 27 01:30:30 EDT 2025 Thu Aug 21 14:14:35 EDT 2025 Fri Sep 05 06:46:49 EDT 2025 Thu Jan 02 22:56:09 EST 2025 Tue Jul 01 03:27:57 EDT 2025 Thu Apr 24 22:51:56 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | S(+)-flurbiprofen R(-)-flurbiprofen plasma flurbiprofen axetil cerebrospinal fluid |
Language | English |
License | Copyright © 2021 Yao, Luo, Zhang, An, Feng and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c465t-e20acbc8adb5b1632fed6725ed6ec0dad14efdfce07a95687a7e45d4bd152d143 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Yoseph Caraco, Hadassah Medical Center, Israel This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology Mojca Kržan, University of Ljubljana, Slovenia These authors have contributed equally to this work. Reviewed by: Andrei Medvedovici, University of Bucharest, Romania |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2021.646196 |
PMID | 33995057 |
PQID | 2528431006 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_78b62f0da91b4e20a3232fa97fa61ac1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8120306 proquest_miscellaneous_2528431006 pubmed_primary_33995057 crossref_citationtrail_10_3389_fphar_2021_646196 crossref_primary_10_3389_fphar_2021_646196 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-04-30 |
PublicationDateYYYYMMDD | 2021-04-30 |
PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in pharmacology |
PublicationTitleAlternate | Front Pharmacol |
PublicationYear | 2021 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Buvanendran (B3) 2006; 104 Matoga (B19) 1999; 49 Zhang (B35) 2007; 64 Kumpulainen (B15) 2010; 70 Sozio (B27) 2013; 18 Wang (B30) 2009; 10 Burian (B2) 2005; 107 Wang (B31) 2019; 9 Mannila (B18) 2006; 45 Tegeder (B29) 2001; 15 Neugebauer (B23) 1995; 275 Sugimoto (B28) 2016; 77 Bishay (B1) 2010; 5 Gulcicek (B12) 2018; 41 Muller (B22) 1991; 42 Ortiz (B25) 2008; 91 Samad (B26) 2001; 410 Ye (B32) 2013; 48 Ohmukai (B24) 1996; 20 Jamali (B13) 1988; 77 Knadler (B14) 1992; 33 Elbaz (B6) 2011; 92 Malmberg (B17) 1994; 256 Memtsoudis (B21) 2019; 44 Debi (B5) 2009; 10 B8 Zhang (B33) 2017; 55 Lee (B16) 2003; 58 Evans (B7) 1992; 42 Geisslinger (B10); 37 Zhang (B34) 2018; 11 Geisslinger (B11) 2000; 74 Geisslinger (B9); 54 Caldwell (B4) 1988; 37 Mehta (B20) 2008; 83 |
References_xml | – volume: 74 start-page: 2094 year: 2000 ident: B11 article-title: Inhibition of Noxious Stimulus-Induced Spinal Prostaglandin E2 Release by Flurbiprofen Enantiomers publication-title: J. Neurochem. doi: 10.1046/j.1471-4159.2000.0742094.x – volume: 37 start-page: 105 year: 1988 ident: B4 article-title: The Metabolic Chiral Inversion and Dispositional Enantioselectivity of the 2-arylpropionic Acids and Their Biological Consequences publication-title: Biochem. Pharmacol. doi: 10.1016/0006-2952(88)90762-9 – volume: 10 start-page: 781 year: 2009 ident: B30 article-title: Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and its Clinical Significance publication-title: Cdm doi: 10.2174/138920009789895480 – volume: 48 start-page: 1099 year: 2013 ident: B32 article-title: Establishment of Stereospecific Assay of Flurbiprofen by High-Performance Liquid-Chromatographic Tandem-Mass Spectrometry and its Application to Pharmacokinetic Study publication-title: Chin. Pharm. J. doi: 10.11669/cpj.2013.13.014 – volume: 70 start-page: 557 year: 2010 ident: B15 article-title: Plasma and Cerebrospinal Fluid Pharmacokinetics of Flurbiprofen in Children publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/j.1365-2125.2010.03720.x – volume: 104 start-page: 403 year: 2006 ident: B3 article-title: Upregulation of Prostaglandin E2and Interleukins in the Central Nervous System and Peripheral Tissue during and after Surgery in Humans publication-title: Anesthesiol. doi: 10.1097/00000542-200603000-00005 – volume: 92 start-page: 1618 year: 2011 ident: B6 article-title: Sex and Body Mass Index Correlate with Western Ontario and McMaster Universities Osteoarthritis Index and Quality of Life Scores in Knee Osteoarthritis publication-title: Arch. Phys. Med. Rehabil. doi: 10.1016/j.apmr.2011.05.009 – volume: 77 start-page: 666 year: 1988 ident: B13 article-title: Stereoselective Pharmacokinetics of Flurbiprofen in Humans and Rats publication-title: J. Pharm. Sci. doi: 10.1002/jps.2600770805 – volume: 256 start-page: 205 year: 1994 ident: B17 article-title: Antinociception Produced by Spinal Delivery of the S and R Enantiomers of Flurbiprofen in the Formalin Test publication-title: Eur. J. Pharmacol. doi: 10.1016/0014-2999(94)90247-x – volume: 42 start-page: 799 year: 1991 ident: B22 article-title: Protein Binding of Indomethacin in Human Cerebrospinal Fluid publication-title: Biochem. Pharmacol. doi: 10.1016/0006-2952(91)90039-8 – volume: 44 start-page: 934 year: 2019 ident: B21 article-title: Risk Factors for Postoperative Delirium in Patients Undergoing Lower Extremity Joint Arthroplasty: a Retrospective Population-Based Cohort Study publication-title: Reg. Anesth. Pain Med. doi: 10.1136/rapm-2019-100700 – volume: 42 start-page: 237 year: 1992 ident: B7 article-title: Enantioselective Pharmacodynamics and Pharmacokinetics of Chiral Non-steroidal Anti-inflammatory Drugs publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/bf00266343 – volume: 83 start-page: 430 year: 2008 ident: B20 article-title: Intravenous Parecoxib Rapidly Leads to COX-2 Inhibitory Concentration of Valdecoxib in the Central Nervous System publication-title: Clin. Pharmacol. Ther. doi: 10.1038/sj.clpt.6100304 – volume: 5 start-page: e10628 year: 2010 ident: B1 article-title: R-flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids publication-title: PLoS One doi: 10.1371/journal.pone.0010628 – volume: 77 start-page: 206 year: 2016 ident: B28 article-title: Topical Anti‐Inflammatory and Analgesic Effects of Multiple Applications of S(+)‐Flurbiprofen Plaster (SFPP) in a Rat Adjuvant‐Induced Arthritis Model publication-title: Drug Dev. Res. doi: 10.1002/ddr.21314 – volume: 37 start-page: 392 ident: B10 article-title: Stereoselective Disposition of Flurbiprofen in Healthy Subjects Following Administration of the Single Enantiomers publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/j.1365-2125.1994.tb04295.x – volume: 18 start-page: 10747 year: 2013 ident: B27 article-title: New Flurbiprofen Derivatives: Synthesis, Membrane Affinity and Evaluation of In Vitro Effect on β-Amyloid Levels publication-title: Molecules doi: 10.3390/molecules180910747 – volume: 58 start-page: 791 year: 2003 ident: B16 article-title: Differences in Flurbiprofen Pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 Genotypes publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/s00228-003-0574-6 – ident: B8 – volume: 15 start-page: 2 year: 2001 ident: B29 article-title: Inhibition of NF‐KB and AP‐1 Activation by R‐ and S‐flurbiprofen publication-title: FASEB j. doi: 10.1096/fj.00-0130fje10.1096/fasebj.15.1.2 – volume: 9 start-page: e01290 year: 2019 ident: B31 article-title: Effect of Flurbiprofen Axetil on Postoperative Delirium for Elderly Patients publication-title: Brain Behav. doi: 10.1002/brb3.1290 – volume: 275 start-page: 618 year: 1995 ident: B23 article-title: Antinociceptive Effects of R(-)- and S(+)-flurbiprofen on Rat Spinal Dorsal Horn Neurons Rendered Hyperexcitable by an Acute Knee Joint Inflammation publication-title: J. Pharmacol. Exp. Ther. – volume: 33 start-page: 369 year: 1992 ident: B14 article-title: Stereoselective Disposition of Flurbiprofen in Normal Volunteers publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/j.1365-2125.1992.tb04054.x – volume: 49 start-page: 477 year: 1999 ident: B19 article-title: Influence of Molecular Lipophilicity on the Diffusion of Arylpropionate Non-steroidal Anti-inflammatory Drugs into the Cerebrospinal Fluid publication-title: Arzneimittelforschung doi: 10.1055/s-0031-1300446 – volume: 55 start-page: 875 year: 2017 ident: B33 article-title: Absorption Kinetics of Flurbiprofen Axetil Microspheres in Cerebrospinal Fluid: A Pilot Study publication-title: Cp doi: 10.5414/CP203092 – volume: 107 start-page: 139 year: 2005 ident: B2 article-title: COX-dependent Mechanisms Involved in the Antinociceptive Action of NSAIDs at Central and Peripheral Sites publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2005.02.004 – volume: 10 start-page: 127 year: 2009 ident: B5 article-title: Differences in Gait Patterns, Pain, Function and Quality of Life between Males and Females with Knee Osteoarthritis: a Clinical Trial publication-title: BMC Musculoskelet. Disord. doi: 10.1186/1471-2474-10-127 – volume: 20 start-page: 203 year: 1996 ident: B24 article-title: Lipo-NSAID Preparation publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/0169-409X(95)00123-O – volume: 91 start-page: 32 year: 2008 ident: B25 article-title: Additive Interaction between Peripheral and Central Mechanisms Involved in the Antinociceptive Effect of Diclofenac in the Formalin Test in Rats publication-title: Pharmacol. Biochem. Behav. doi: 10.1016/j.pbb.2008.06.008 – volume: 410 start-page: 471 year: 2001 ident: B26 article-title: Interleukin-1β-mediated Induction of Cox-2 in the CNS Contributes to Inflammatory Pain Hypersensitivity publication-title: Nature doi: 10.1038/35068566 – volume: 41 start-page: 264 year: 2018 ident: B12 article-title: Role of Diclofenac Sodium and Paracetamol on Colonic Anastomosis: An Experimental Rodent Model publication-title: Asian J. Surg. doi: 10.1016/j.asjsur.2017.01.002 – volume: 45 start-page: 737 year: 2006 ident: B18 article-title: Cerebrospinal Fluid Distribution of Ketoprofen after Intravenous Administration in Young Children publication-title: Clin. Pharmacokinet. doi: 10.2165/00003088-200645070-00008 – volume: 64 start-page: 67 year: 2007 ident: B35 article-title: Influence of CYP2C9 and CYP2C19 Genetic Polymorphisms on Pharmacokinetics of Gliclazide MR in Chinese Subjects publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/j.1365-2125.2007.02846.x – volume: 11 start-page: 3061 year: 2018 ident: B34 article-title: Population Pharmacokinetic Modeling of Flurbiprofen, the Active Metabolite of Flurbiprofen Axetil, in Chinese Patients with Postoperative Pain publication-title: Jpr doi: 10.2147/JPR.S176475 – volume: 54 start-page: Pl173 ident: B9 article-title: Antinociceptive Actions of R(−)-flurbiprofen - a Non-cyclooxygenase Inhibiting 2-arylpropionic Acid - in Rats publication-title: Life Sci. doi: 10.1016/0024-3205(94)00555-9 |
SSID | ssj0000399364 |
Score | 2.2877097 |
Snippet | Background:
Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through... Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a... Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 646196 |
SubjectTerms | cerebrospinal fluid flurbiprofen axetil Pharmacology plasma R(-)-flurbiprofen S(+)-flurbiprofen |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELZQT1wQ_4Q_GQlVLdR01-u1s8cQERUkUASt1Jtlr211q-BWaYroG3DmDXg1noQZO02zCMGFyyq79saWv1nPN7L9DSHPK-mlA8_GArgPBgxcMQs0g1VyaHgoPThFPDv8_oPcOxDvDuvDtVRfuCcsywPngdtVQyt5KJxpSis8L0wFHCCYRgUjS9OmwKdoirVgKs3B6HelyMuYEIU1u-H0yKD-Jy9fSQFRg-w5oqTX_yeS-fteyTXnM7lJbixZIx3l3t4i13y8TTanWXb6YofuX52iOtuhm3R6JUh9cYf8gGI6XiUcpCeBToE0fzbUREfHfg5xMaYPwSYms_PO0Y9bP79932ap_NPWy20Gj-e2wwTfPsJfxdxPBJWOMMs4fYv3X5LgK_w-Thu8Uku9N0df_aKb0S7StHhAYdrCqmd3ycHkzf54jy1TM7BWyHrBEIjWtkPjbG2B0vHgnVS8hqtvASxXCh9caH2hDB5IVEZ5UTthHfAFKKzukY14Ev0DQnkRgpONMkVohAKUG87bViqYpUtbWTMgxSVOul3qlmP6jJmG-AWh1QlajdDqDO2AvFi9cppFO_5W-TWCv6qIetvpAVihXlqh_pcVDsizS9PR8H3ioouJHoZc8xoIAK6iQEP3symtmqrwXDEQ5gFRPSPr9aVfErujpAEOvAyjvYf_o_OPyHUcj7xG9phsLObn_glQrYV9mr6qX1_dK_4 priority: 102 providerName: Directory of Open Access Journals |
Title | The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration After Intravenous Injection of Flurbiprofen Axetil in Human Subjects |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33995057 https://www.proquest.com/docview/2528431006 https://pubmed.ncbi.nlm.nih.gov/PMC8120306 https://doaj.org/article/78b62f0da91b4e20a3232fa97fa61ac1 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLbGuOEGbfx2jMlIaNpgGYmT2M0FQqWiGkhDFazS7iL_skxdOtIOrW_ANW_Aq_EknOOkHUEVV9xESWzHjo_t852c-DuEPI-55QY0W-BAfQSAwEWgAGYEMe9K5iILShH3Dh9_5Eej5MNperpGFuGtmg6crjTtMJ7UqBofXn-dv4EJ_xotTtC3r9zlmURqTxYd8gQMAn6L3AbFxNEWO27Qvl-YURnzpPZtri7Z0k6exH8V8vz7B8o_NNJgg9xtoCTt1bLfJGu2vEd2hzUX9fyAntxsrZoe0F06vGGpnt8nPyGZ9pdRCOnE0SEg6QtJZWlo31ZgLGNMEaxiML4qDP209-v7j_3Ap3_ee7kfwO1KFRj125bwqLJuJ0qa9jD0OH2P1988Cyycn_u_vnxNrZK9azsrxrQoqfcoUFjLMOv0ARkN3p30j4ImXkOgE57OAstCqZXuSqNSBTiPOWu4YCkcrQ6NNFFinXHahkLiLkUhhU1SkygDIAIS44dkvZyU9jGhLHTO8EzI0GWJyCKVMaY1F7B0RypWskPChZxy3ZCZY0yNcQ5GDYo296LNUbR5LdoOebEsclkzefwr81sU_jIjknD7G5PqS97M6Vx0FWcOXgzal-DLxwBPncyEkzySOuqQZ4uhk8OkRU-MLC10ec5SQAXoWoGKHtVDaVlVjJuNAUV3iGgNslZb2illceaJwQGsoQm49T8a_4Tcwf6oHWfbZH1WXdmngL9masd_t9jxc-s3IVQ1LA |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Comparison+of+Plasma+and+Cerebrospinal+Fluid+R%28%E2%88%92%29-+and+S%28%2B%29-Flurbiprofen+Concentration+After+Intravenous+Injection+of+Flurbiprofen+Axetil+in+Human+Subjects&rft.jtitle=Frontiers+in+pharmacology&rft.au=Han+Yao&rft.au=Xingxian+Luo&rft.au=Hong+Zhang&rft.au=Haiyan+An&rft.date=2021-04-30&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=12&rft_id=info:doi/10.3389%2Ffphar.2021.646196&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_78b62f0da91b4e20a3232fa97fa61ac1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |